Competition Increases Between Novartis, Lilly & Pfizer For Approval Of New Breast Cancer Drug

Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.